DOCETAXEL\DOCETAXEL ANHYDROUS for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where DOCETAXEL\DOCETAXEL ANHYDROUS was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for DOCETAXEL\DOCETAXEL ANHYDROUS
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 409 | 10.7% | 129 | 195 |
| Myelosuppression | 404 | 10.6% | 10 | 246 |
| Disease progression | 289 | 7.6% | 65 | 46 |
| Off label use | 281 | 7.3% | 51 | 115 |
| Nausea | 279 | 7.3% | 92 | 104 |
| Neutropenia | 250 | 6.5% | 46 | 85 |
| Fatigue | 236 | 6.2% | 107 | 73 |
| Pyrexia | 221 | 5.8% | 75 | 109 |
| Vomiting | 216 | 5.6% | 79 | 93 |
| Asthenia | 190 | 5.0% | 71 | 59 |
| Anaemia | 188 | 4.9% | 29 | 79 |
| Drug ineffective | 184 | 4.8% | 39 | 42 |
| Decreased appetite | 172 | 4.5% | 74 | 53 |
| Dyspnoea | 162 | 4.2% | 82 | 39 |
| Febrile neutropenia | 155 | 4.1% | 40 | 91 |
Other Indications for DOCETAXEL\DOCETAXEL ANHYDROUS
Breast cancer (791)
Product used for unknown indication (388)
Her2 positive breast cancer (216)
Breast cancer metastatic (200)
Prostate cancer (182)
Breast cancer female (159)
Invasive ductal breast carcinoma (149)
Prostate cancer metastatic (116)
Lung adenocarcinoma (114)
Chemotherapy (107)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)